Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures

Ping Sui,Xueping Liu,Cheng Zhong,Zhanming Sha

DOI: https://doi.org/10.1038/s41598-024-61629-8

IF: 4.6

2024-05-14

Scientific Reports

Abstract:In addition to presenting significant diagnostic and treatment challenges, lung adenocarcinoma (LUAD) is the most common form of lung cancer. Using scRNA-Seq and bulk RNA-Seq data, we identify three genes referred to as HMR, FAM83A, and KRT6A these genes are related to necroptotic anoikis-related gene expression. Initial validation, conducted on the GSE50081 dataset, demonstrated the model's ability to categorize LUAD patients into high-risk and low-risk groups with significant survival differences. This model was further applied to predict responses to PD-1/PD-L1 blockade therapies, utilizing the IMvigor210 and GSE78220 cohorts, and showed strong correlation with patient outcomes, highlighting its potential in personalized immunotherapy. Further, LUAD cell lines were analyzed using quantitative PCR (qPCR) and Western blot analysis to confirm their expression levels, further corroborating the model's relevance in LUAD pathophysiology. The mutation landscape of these genes was also explored, revealing their broad implication in various cancer types through a pan-cancer analysis. The study also delved into molecular subclustering, revealing distinct expression profiles and associations with different survival outcomes, emphasizing the model's utility in precision oncology. Moreover, the diversity of immune cell infiltration, analyzed in relation to the necroptotic anoikis signature, suggested significant implications for immune evasion mechanisms in LUAD. While the findings present a promising stride towards personalized LUAD treatment, especially in immunotherapy, limitations such as the retrospective nature of the datasets and the need for larger sample sizes are acknowledged. Prospective clinical trials and further experimental research are essential to validate these findings and enhance the clinical applicability of our prognostic model.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to address the diagnostic and treatment challenges of lung adenocarcinoma (LUAD), especially by identifying gene signatures related to necroptotic anoikis to improve the prediction accuracy of responses to PD - 1/PD - L1 immunotherapy. Specifically, the researchers used single - cell RNA sequencing (scRNA - Seq) and bulk RNA sequencing (bulk RNA - Seq) data to identify three genes related to necroptotic apoptosis (HMR, FAM83A, and KRT6A), and constructed a prediction model through these genes. This model can divide LUAD patients into high - risk and low - risk groups and shows significant survival differences. In addition, this model was also used to predict responses to PD - 1/PD - L1 blockade therapy, and the results showed a strong association with patient prognosis, thus demonstrating potential application value in personalized immunotherapy.

The key points of the study include:
1. **Identifying key genes**: Through scRNA - Seq and bulk RNA - Seq data, three genes (HMR, FAM83A, and KRT6A) related to necroptotic apoptosis were identified.
2. **Validating the model**: Preliminary validation was carried out on the GSE50081 dataset, proving that the model can effectively distinguish between high - risk and low - risk patients and shows significant survival differences.
3. **Predicting immunotherapy responses**: Using the IMvigor210 and GSE78220 cohorts, the model was further applied to predict responses to PD - 1/PD - L1 blockade therapy, and the results were strongly correlated with patient prognosis.
4. **Molecular mechanism research**: Through qPCR and Western blot analysis, the expression levels of these genes in LUAD cell lines were confirmed to further validate the relevance of the model.
5. **Mutation landscape analysis**: The mutation status of these genes was explored to reveal their broad impact in multiple cancer types.
6. **Molecular sub - clustering**: Through molecular sub - clustering analysis, different expression profiles and their associations with different survival outcomes were revealed, emphasizing the application potential of the model in precision oncology.
7. **Immune cell infiltration diversity**: The relationship between necroptotic gene signatures and immune cell infiltration was analyzed to explore their potential significance in the immune escape mechanism in LUAD.

Overall, this study identified gene signatures related to necroptotic apoptosis by comprehensively analyzing single - cell and bulk RNA sequencing data, constructed a prediction model, improved the prediction accuracy of responses to PD - 1/PD - L1 immunotherapy, and provided a new strategy for personalized lung cancer treatment.